FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

M.G.L. c.112 §39J bars out-of-state pharmacies from shipping or dispensing drug preparations into Massachusetts unless the pharmacy holds a non-resident license. §39F and §39J(d) also require a non-resident sterile compounding license, or a non-resident complex non-sterile compounding license, for those preparations. The Board's Nov. 19, 2024 memo set enforcement for May 1, 2025 and says every prescription dispensed into Massachusetts must be patient-specific. Under 247 CMR 6.02 and 6.09, a non-resident Drug Store Pharmacy license requires a Board-approved inspection within 2 years. Sterile and complex non-sterile licenses require a satisfactory inspection before licensure and within 1 year for each application and renewal. Accepted inspections are by a resident-state inspector using NABP Universal/Blueprint forms, or by NABP or Gates Healthcare Associates. At least one pharmacist at the pharmacy must hold a Massachusetts license and act as the 'Designated Pharmacist-in-Charge' (required by rule for controlled-substance shippers and compounding licenses; Board FAQ applies it to every non-resident pharmacy). Non-resident pharmacies must also report Schedule II–V drugs and gabapentin to the Massachusetts PMP (c.94C §24A, no waiver).

Confirmed: licensure required since May 1, 2025, after a grace period for applications through Mar. 31, 2025. Mass.gov blocks automated fetchers, so these pages were read in a browser. The rule and FAQ differ on the Massachusetts-licensed pharmacist: 247 CMR 6.09(1)(c) requires one only for pharmacies shipping controlled substances (and for compounding licenses), while the Board FAQ says every non-resident pharmacy needs one. The Board offers no non-resident licenses for wholesalers, manufacturers or 3PLs.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Board Policy 2023-07 (revised Feb. 6, 2025) states that 'Patient-specific prescriptions are required to dispense any compounded preparation into, within, or from Massachusetts.' M.G.L. c.112 §39F(c) covers any entity compounding sterile or complex non-sterile preparations 'in volumes inconsistent with routinely observed volume patterns associated with patient-specific prescriptions or in the absence of accountability documentation'. Such entities must follow cGMP and register with FDA as a manufacturer, or register as an outsourcing facility with both FDA (503B) and the Board (§36E). The Board's Nov. 2024 non-resident memo repeats that any prescription dispensed into Massachusetts must be patient-specific. This matches FDA's view that 503A covers only patient-specific compounding.

The older stand-alone sterile compounding rules (247 CMR 17.00) no longer appear on the Board's regulations list, and 247 CMR 2.00 and 9.00 do not use the term 'office use'. The patient-specific requirement rests on the statute and Board policy above. Mass.gov blocks automated fetchers, so the policy was read in a browser.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Under M.G.L. c.112 §36E(c), the Board registers out-of-state entities as non-resident outsourcing facilities. §39J(d) bars any outsourcing facility operating outside Massachusetts from shipping, selling or dispensing sterile or complex non-sterile preparations into the state unless it holds that registration. Applicants must show a current FDA 503B registration, an FDA inspection in connection with 503B within the 2 years before applying, and eligibility for a Massachusetts controlled substances registration (§36E(c); 247 CMR 21.04). A good-standing letter from the home state (if it licenses the facility) is also required. Registrations expire December 31 of each odd-numbered year. The Board may deny or revoke one after an FDA warning letter that prohibits commercial distribution or a failure to follow cGMP. The Board's online application lists a $750 non-resident fee.

Mass.gov blocks automated fetchers, so the rule PDF and how-to page were read in a browser. The 247 CMR 21.00 page did not show an effective date. The Board FAQ confirms non-resident registration exists for 503B facilities but not for wholesalers, manufacturers or 3PLs.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Massachusetts is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

M.G.L. c. 94C Sec. 7(a) requires every person (other than pharmacies, wholesalers and outsourcing facilities) who dispenses or possesses with intent to dispense any controlled substance in Massachusetts to register with the Commissioner of Public Health, on payment of a fee set annually by the Commissioner of Administration. 'Dispense' expressly includes prescribing and administering (c. 94C Sec. 1). The registration is effective for one year from issuance or until the end of the term of the registrant's professional license under chapter 112, whichever is later, so in practice it tracks the professional license cycle. DEA registration requires state authority to handle controlled substances, so the MCSR comes first.

mass.gov (DPH program pages) returned 403 in this session, so the fee amount, NP/PA registration details and any per-location rules in DPH regulations were not confirmed from the agency. The statute says 'commissioner of public health'; the program name 'MCSR' was not confirmed from a page opened in this session. Because the term runs to the end of the professional license term, renewal tracks the Board license cycle.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

M.G.L. c. 94C, s. 24A requires DPH regulations mandating PMP use each time a prescription for a narcotic drug in Schedule II or III, or a benzodiazepine, is issued, and lets DPH add commonly misused Schedule IV or V drugs. 105 CMR 700.012(G) implements this: practitioners must use the PMP before prescribing any opioid in Schedule II or III or a benzodiazepine, and before a Schedule IV or V drug designated in DPH guidance. Exceptions: hospice care; emergencies where checking is likely to harm the patient; system outages; DPH waivers; and other exceptions in DPH guidance. Enforced by DPH's Drug Control Program and the licensing boards.

Source older than 2 years - possibly stale (105 CMR 700.012 last amended eff. 2/3/2023 per the text read). Frequency: each prescription. Testosterone is a Schedule III non-narcotic, so it is not caught unless DPH changes its rules (DPH's add-on authority covers only Schedule IV/V). mass.gov pages (including DPH guidance listing any designated Schedule IV/V drugs) returned 403 to automated access and were not reviewed.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

M.G.L. c. 94C, 9(b) limits practitioner dispensing to a single dose or the quantity needed for immediate and proper treatment until a prescription can be filled at a pharmacy; all other ongoing medication must go through a prescription. Because Massachusetts classifies every prescription drug not in Schedules I-V as Schedule VI (c. 94C, 3), this limit reaches all prescription drugs, not only narcotics. Exceptions include free manufacturer samples and indigent-program drugs in original packaging, family-planning (Title X) programs and licensed clinics under 9(e), and therapeutic contact lenses.

In-office administration is not affected by this dispensing limit. A Massachusetts Controlled Substance Registration is needed for any controlled substance activity.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

The Board of Registration in Medicine states there is no special telemedicine license; a full license is required. Its Policy on Telemedicine (October 6, 2022) says no face-to-face encounter is required before telemedicine and the standard of care is the same as in person; its internet-prescribing guidance requires an adequate history and appropriate physical and/or mental status exam for a valid controlled-substance prescription. No Massachusetts telehealth-specific Schedule III limit was found. IMLC: not a member.

mass.gov blocked the research tools, so board documents were read through CCHP's quotations. Massachusetts also requires a state Controlled Substance Registration to prescribe testosterone.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Board of Registration in Medicine rule 243 CMR 2.07(4) provides that there shall be no delegation of medical services to an individual who is not licensed to perform those services in Massachusetts, so unlicensed staff (e.g. estheticians, medical assistants) cannot be delegated injections. Board of Registration in Nursing rule 244 CMR 3.02 says RNs implement prescribed medical and therapeutic regimens within their education and experience. The Nursing Board's advisory rulings, which may add conditions for aesthetic injections, are published on mass.gov, which returned HTTP 403 to automated requests on 2026-09-23.

Check the Board of Registration in Nursing advisory rulings on mass.gov directly. The 243 CMR 2.07(4) wording is from a fetched summary of the LII text.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

RNs implement prescribed regimens under 244 CMR 3.02, and physicians may not delegate medical services to unlicensed individuals (243 CMR 2.07(4)). Nebraska's 2023 IV opinion cites Massachusetts BORN Advisory Ruling 9324 on accepting, verifying, transcribing and implementing prescriber orders, but Massachusetts-specific IV-hydration requirements (individual exams, standing orders, mobile services) were not confirmed.

Check the Board of Registration in Nursing advisory rulings (mass.gov).

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies Massachusetts as strict, citing M.G.L. c. 112 §§2–12, M.G.L. c. 156A and c. 156C, and McMurdo v. Getter (1937). Board of Registration in Medicine rule 243 CMR 2.07(22)(a) lists the entities through which licensees may practise (professional corporations, nonprofits, LLCs and partnerships under specified statutes). MedPath Compliance reports H.5159 (signed 2025-01-08) adding notice requirements for private equity, REIT and MSO transactions and sale-leaseback limits.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

243 CMR 2.07(4) provides that there shall be no delegation of medical services to an individual who is not licensed to perform those services in Massachusetts. No Massachusetts rule creating a laser-technician credential was found; Department of Public Health laser regulations and any electrologist laser rules on mass.gov could not be accessed on 2026-09-23.

'No' here means licensed practitioners only (no delegation to unlicensed staff); whether RNs may perform cosmetic laser procedures under BORN guidance was not confirmed. A vendor compilation reports that Massachusetts electrologists and estheticians may perform laser hair removal under physician supervision after 1,100 hours of training — unverified.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

M.G.L. c.111D §4 provides that no person shall maintain a clinical laboratory 'in the commonwealth apart from a hospital or clinic' without a Department of Public Health license. Exemptions include certain physician-office labs, CLIA-waived testing sites, research and teaching labs, and health screening programs. Section 8 separately limits testing to written requests from licensed practitioners (see the direct-access topic).

Out-of-state labs: not covered by §4.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

M.G.L. c.111D §8 bars clinical laboratories from examining specimens except on the written request of a licensed physician, dentist, chiropractor, podiatrist, osteopath or other listed requester (including DPH-licensed substance abuse programs and state agencies). The exceptions are internal quality control and health-promotion screening programs not used for diagnosis or treatment. Results go only to the requester.

Practitioner-ordered panels are unaffected. Nurse practitioners and PAs are not named in the summary of §8 that was reviewed; confirm their ordering authority under their own practice laws.

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Massachusetts is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Massachusetts does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

Pending: Massachusetts bills (e.g., H 4870 of 2026 and S 1504 of 2025) would ban intentionally added PFAS in children's cosmetics (proposed Jan 1, 2029). Not enacted as of the March 2026 compilation. The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.